Upadacitinib vs. Infliximab for Severe Ulcerative Colitis
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with acute severe ulcerative colitis (ASUC)—a serious, sudden flare of your ulcerative colitis
- Age 18 or older
- No allergy or previous severe reaction to upadacitinib or infliximab
- No current or recent cancer diagnosis
- No serious heart, lung, liver, or kidney disease
- Not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a newer medication called upadacitinib to traditional steroids for treating acute severe ulcerative colitis (sudden worsening of UC with bloody diarrhea and urgent symptoms). The goal is to see which approach works better as a first treatment.
This trial tests whether giving two medicines together (infliximab and tofacitinib) is safe and effective for people hospitalized with a severe flare of ulcerative colitis. The goal is to see if the combination works better than standard care to help you recover faster.
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
This study tests whether upadacitinib, a pill that calms the immune system, can help people hospitalized with a severe flare of ulcerative colitis. It aims to see if the drug can reduce symptoms and help you leave the hospital sooner.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
Hear when a new Acute Severe Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.